No idea, which is why I'm still mainly focusing on iTrack...

No idea, which is why I'm still mainly focusing on iTrack Advance as a sole driver of returns, but adding in a little line here and there about 2RT + the R&D pipeline. Of course 2RT represents a game changer but that'll likely be a treat for the true long term investors. iTrack Advance on the other hand is happening now, and we can clearly see just how massive it is becoming in the ophthalmology industry. Significantly differentiated to other products it's basically in a league of its own (ie it's "real canaloplasty" as the company puts it). This has been driving rapid adoption...

In relation to negotiating a deal like this they can be a massive pain really, especially in a tough market like this. You might spend many months going through a process with one party, and then just before you reach the finish line some little issue causes them to decide to pull out, restarting the whole process over again. Nova Eye will also likely need a very large deal to fund 2RT which doesn't make it much easier to negotiate!